Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy.
Albumin
Globulin
Prostate cancer
Radical prostatectomy
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
27
01
2021
accepted:
26
05
2021
pubmed:
30
6
2021
medline:
30
6
2021
entrez:
29
6
2021
Statut:
ppublish
Résumé
To evaluate the potential predictive value of the preoperative serum albumin to globulin ratio (AGR) for oncological outcomes in patients treated with radical prostatectomy (RP) for clinically non-metastatic prostate cancer (PCa). Pre-operative AGR was assessed in a multi-institutional cohort of 6041 patients treated with RP. Logistic regression analyses were performed to assess the association of the AGR with advanced disease. We performed Cox regression analyses to determine the relationship between AGR and biochemical recurrence (BCR). The optimal cut-off value was determined to be 1.31 according to receiver operating curve analysis. Compared to patients with a higher AGR, those with a lower preoperative AGR had worse BCR-free survival (P < 0.01) in the Kaplan-Meier analysis. Pre- and post-operative multivariable models that adjusted for the effects of established clinicopathologic features, confirmed its independent association with BCR [hazard ratio (HR) 1.52, 95% confidence interval (CI) 1.31-1.75, P < 0.01, HR 1.55, 95% CI 1.34-1.79, P < 0.01, respectively]. However, the addition of AGR to established prognostic models did not improve their discrimination. While AGR is significantly associated with BCR, in the present study, the clinical impact of AGR was not large enough to affect patient management. Longer follow-up is necessary to observe the true effect of AGR.
Identifiants
pubmed: 34184136
doi: 10.1007/s10147-021-01952-6
pii: 10.1007/s10147-021-01952-6
pmc: PMC8364901
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1729-1735Informations de copyright
© 2021. The Author(s).
Références
Int J Colorectal Dis. 2013 Dec;28(12):1629-36
pubmed: 23857599
Clin Cancer Res. 2008 Jun 15;14(12):3785-91
pubmed: 18559597
N Engl J Med. 1999 Feb 11;340(6):448-54
pubmed: 9971870
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Future Oncol. 2009 Dec;5(10):1555-84
pubmed: 20001796
Am J Surg. 2013 Nov;206(5):764-70
pubmed: 23866764
Prostate. 2007 May 1;67(6):614-22
pubmed: 17299799
Asian Pac J Cancer Prev. 2014;15(15):6449-53
pubmed: 25124641
J Clin Oncol. 2006 Aug 20;24(24):3973-8
pubmed: 16921049
Acta Oncol. 2011 Jun;50 Suppl 1:61-75
pubmed: 21604943
J Urol. 2004 Mar;171(3):1122-7
pubmed: 14767284
Urol Oncol. 2010 Jul-Aug;28(4):389-400
pubmed: 20610277
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
BMC Cancer. 2015 May 02;15:347
pubmed: 25934494
J Clin Oncol. 2004 May 1;22(9):1655-63
pubmed: 15117988
BJU Int. 2007 Dec;100(6):1254-8
pubmed: 17979925
Asian J Androl. 2018 Jul 17;:
pubmed: 30027930
Biomed Res Int. 2017;2017:3083267
pubmed: 28424782
Eur Urol. 2010 Nov;58(5):687-700
pubmed: 20727668
Eur Urol. 2007 Dec;52(6):1601-9
pubmed: 17919807
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Nutr Cancer. 2021;73(1):75-82
pubmed: 32148098
PLoS One. 2014 Apr 09;9(4):e94473
pubmed: 24718309
BJU Int. 2006 Aug;98(2):329-34
pubmed: 16879673
BJU Int. 2008 Jun;101(12):1513-8
pubmed: 18422773